ArticleNeuropsychopharmacology reports2025
Memantine Exacerbates Trimethyltin-Induced Neurodegeneration and Delays Cognitive Impairment Recovery.
Article in Neuropsychopharmacology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Transcriptomic Challenges We Faced with Animal Models for Neurological Disorders.Current issues in molecular biology · 2026Review
- C3H mouse model of Alzheimer's disease: Blood markers, proteomic biomarkers, cognitive ability, and histopathology.Open veterinary journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trimethyltin (TMT), a type of organotin compound, induces neuronal loss in specific brain regions and cognitive impairments. These changes are transient and followed by recovery, thereby indicating a model of transient brain damage. Memantine (MEM) has neuroprotective properties. However, its effects against neurodegeneration during brain injury are inconsistent. The current study aimed to elucidate the effects of early MEM treatment on the outcomes of brain injury. Memantine at a dose of 10 mg/kg was administered for three consecutive days starting immediately after the administration of TMT at a dose of 2.6 mg/kg. We evaluated neuronal loss and cognitive function in the hippocampal dentate gyrus 3 or 7 days after TMT administration. Results showed that MEM had no significant impact on working memory impairment 3 days after TMT administration. However, it significantly worsened cognitive function 7 days after TMT administration. Furthermore, Fluoro-Jade B staining revealed that MEM exacerbated neuronal degeneration induced by TMT administration. Based on these findings, early MEM treatment after TMT administration could exacerbate hippocampal neurodegeneration and cognitive impairment. Therefore, at least in the early stages of brain injury, MEM administration can worsen the prognosis of transient neuronal degeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.